Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease course, survival, and genetic heterogeneity in chorea-acanthocytosis: a case series of 34 patients.

Journal of movement disorders·2026
Same author

Multiple Sclerosis in a Person With Hirschprung's Disease: A Case Report.

Clinical case reports·2026
Same author

Spinocerebellar Ataxia Type 12: Spectrums of Movement Disorders and Clinical Features.

Neuro-degenerative diseases·2026
Same author

Multiple sclerosis during an emergency or crisis: A narrative review focused on the effect of war and COVID-19 pandemic.

Multiple sclerosis and related disorders·2026
Same author

Pregnancy among women with neuromyelitis optica spectrum disorder: An updated case series from Iran.

Multiple sclerosis and related disorders·2026
Same author

Fingolimod for pediatric multiple sclerosis: The Ped-MS group systematic review and meta-analysis.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: May 8, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

Does levetircetam decrease of the rubral tremor in patients with multiple sclerosis.

Ahmad Chitsaz1, Noushin Mehrbod, Masoud Etemadifar

  • 1Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences
|August 21, 2013
PubMed
Summary

Levetiracetam effectively reduced tremor in Multiple Sclerosis (MS) patients during treatment. However, tremor symptoms returned after the medication washout period, indicating a temporary effect.

Keywords:
Levetiracetammultiplesclerosistremor

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: May 8, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Tremor is a common and disabling symptom in Multiple Sclerosis (MS).
  • Effective management of MS-related tremor remains a significant clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of Levetiracetam in treating tremor associated with Multiple Sclerosis.

Main Methods:

  • A clinical trial involving 20 Multiple Sclerosis patients.
  • Administered Levetiracetam with a dose escalation protocol.
  • Assessed tremor severity at baseline, post-intervention, and post-washout periods.

Main Results:

  • Levetiracetam significantly decreased tremor rates in MS patients (P = 0.001).
  • The medication was well-tolerated with no serious adverse events observed.
  • Tremor recurrence was noted after the washout period.

Conclusions:

  • Levetiracetam demonstrates efficacy in reducing tremor in Multiple Sclerosis patients.
  • The tremor-reducing effects of Levetiracetam appear to be temporary, as symptoms returned post-washout.